brodalumab

Modality

mAb

Mechanism

12.1 Mechanism of Action Brodalumab is a human monoclonal IgG2 antibody that selectively binds to human IL-17RA and inhibits its interactions with cytokines IL-17A, IL-17F, IL-17C, IL-17A/F heterodimer, and IL-25. IL-17RA is a protein expressed on the cell surface and is a required component of receptor complexes utilized by multiple IL-17 family cytokines. Blocking IL-17RA inhibits IL-17 cytokine-induced responses including the release of pro-inflammatory cytokines and chemokines.

Targets

Interleukin-17 receptor A, Interleukin-17 receptor B, Interleukin-17 receptor C, Interleukin-17 receptor D, Interleukin-17 receptor E, Interleukin-17A

Storage

—

Approved

psoriasis — FDA

In trial

psoriasis, hidradenitis suppurativa, acne vulgaris

Source

DailyMed label

Last verified

2026-04-19

No curated MOA diagram yet. See lib/moa-data.ts for the shape; add an entry keyed by brodalumab.